Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Apr 18;16(1):12.
doi: 10.1186/s40246-022-00384-1.

The role of m6A methylation in osteosarcoma biological processes and its potential clinical value

Yanjiao Wu #  1   2 , Zhiyun Wang #  1 , Jianlin Shen  3 , Wei Yan  4 , Shurong Xiang  2 , Huan Liu  5 , Wenhua Huang  6   7   8   9
Affiliations
Review

The role of m6A methylation in osteosarcoma biological processes and its potential clinical value

Yanjiao Wu et al. Hum Genomics. .

Abstract

Osteosarcoma (OS) is the most common primary malignant bone tumor in children and young adults and has a poor prognosis. Recent developments in the field of high-throughput sequencing technology, particularly in methylated RNA immunoprecipitation sequencing (MeRIP-seq), have led to renewed interest in RNA methylation. Among the various RNA modifications, N6-methyladenosine (m6A) modifications are the most common. Emerging evidence suggests that m6A methylation can affect the complexity of cancer progression by regulating biological functions related to cancer. In this review, we will shed light on recent findings regarding the biological function of m6A methylation in OS and discuss future research directions and potential clinical applications of RNA methyltransferases in OS.

Keywords: Epigenetics; Erasers; Osteosarcoma; Readers; Writers; m6A modification.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
The potential roles of RNA m6A modification in osteosarcoma. m6A regulates the differential expression of oncogenes and tumor suppressor genes, which contributes to processes involved in the development of osteosarcoma, including cell proliferation, apoptosis, invasion, migration, metastasis, clinical prognosis, chemotherapy and radiotherapy resistance
See this image and copyright information in PMC

References

    1. Lin YH, Jewell BE, Gingold J, Lu L, Zhao R, Wang LL, et al. Osteosarcoma: molecular pathogenesis and iPSC modeling. Trends Mol Med. 2017;23(8):737–755. doi: 10.1016/j.molmed.2017.06.004. - DOI - PMC - PubMed
    1. Smrke A, Anderson PM, Gulia A, Gennatas S, Huang PH, Jones RL. Future directions in the treatment of osteosarcoma. Cells-Basel. 2021;10(1):172. doi: 10.3390/cells10010172. - DOI - PMC - PubMed
    1. Smeland S, Bielack SS, Whelan J, Bernstein M, Hogendoorn P, Krailo MD, et al. Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort. Eur J Cancer. 2019;109:36–50. doi: 10.1016/j.ejca.2018.11.027. - DOI - PMC - PubMed
    1. Klein MJ, Siegal GP. Osteosarcoma: anatomic and histologic variants. Am J Clin Pathol. 2006;125(4):555–581. doi: 10.1309/UC6K-QHLD-9LV2-KENN. - DOI - PubMed
    1. Jamali Z, Taheri Anganeh M, Shabaninejad Z, Keshavarzi A, Taghizadeh H, Razavi ZS, et al. Autophagy regulation bymicroRNAs: novel insights into osteosarcoma therapy. IUBMB Life. 2020;72(7):1306–1321. doi: 10.1002/iub.2277. - DOI - PubMed

Publication types